Key Takeaways Medifast posted a Q3 loss of $0.21 per share, wider than the expected $0.01 loss.Revenues fell 36.2% to $89.4M, caused by a 35% drop in active OPTAVIA coaches.The company is pivoting from weight loss to a broader metabolic health strategy.Medifast, Inc. ((MED) delivered third-quarter 2025 results, with the top line surpassing the Zacks Consensus Estimate while the bottom line missing the same. Both the metrics showed a year-over-year decline.Management is shifting its strategy from being a wei ...

Core Viewpoint - Skye Bioscience, Inc. is set to discuss its Q1 2025 financial results in a conference call on May 8, 2025, highlighting its focus on therapeutic pathways for obesity and metabolic health disorders [1][2]. Company Overview - Skye Bioscience is a clinical-stage biotechnology company dedicated to developing next-generation molecules that target G-protein coupled receptors for metabolic health [3]. - The company is conducting a Phase 2 clinical trial for nimacimab, an antibody that inhibits CB1, and is also evaluating its combination with a GLP-1R agonist (Wegovy®) [3]. Upcoming Events - A conference call will take place on May 8, 2025, at 1:30 p.m. PT/4:30 p.m. ET to discuss the company's financial results, with an earnings press release to be issued after market close on the same day [1][2].